MANAGEMENT

GREG YAP   CHIEF EXECUTIVE OFFICER AND CO-FOUNDER

Greg YapGreg is an entrepreneurial leader and general manager who specializes in building growing companies in life science technologies, translational medicine, and medical diagnostics. Greg was most recently the first healthcare Entrepreneur in Residence at GE, where he led strategic assessment for novel GE technology. Previously, Greg was Lifecycle Leader, Advanced Staining Assays, at Ventana / Roche Diagnostics, with responsibility for its market-leading ~$500M cancer diagnostic assay business, whose products help guide treatment for nearly half of cancer patients worldwide. Greg was Chief Operating Officer of CELLective Dx (circulating tumor cells) and held multiple general management roles at Affymetrix (microarrays) including VP Molecular Diagnostics and VP DNA Products. Greg has worked in venture capital with Bay City Capital and in management consulting with McKinsey & Company. He is a board director of Outward Bound California and Outward Bound Services Group. Greg received his MBA from Stanford University and his AB in molecular biology, summa cum laude, from Princeton University.

JOSHUA SALAFSKY, PhD   FOUNDER AND CHIEF SCIENTIFIC OFFICER

Joshua SalafskyJosh is the Founder of Biodesy and the inventor of the SHG technique for studying biological molecules. He has managed Biodesy, raised angel financing, was awarded a number of grants from the NSF and NIH, and obtained the key scientific results that galvanized the scientific and venture capital communities. Josh met Greg during the Series A financing and they completed this milestone together. Josh was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. His expertise and interests are in the areas of Biophysics and Physical Chemistry. Josh received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis which converts light into chemical energy.

ARIEL NOTCOVICH, PhD   VICE PRESIDENT OF PRODUCT DEVELOPMENT

Ariel NotcovichAriel G. Notcovich is an accomplished Research and Development (R&D) executive, with a wide experience in all aspects and stages of product development for life science markets, having worked in startup as well as in corporate environments. Ariel founded ProteOptics during his PhD in Physics at the Technion-Israel Institute of Technology and served as its CSO and CEO. The company developed a multichannel Surface Plasmon Resonance imaging system for the label-free analysis of molecular interactions. ProteOptics was acquired by Bio-Rad Laboratories. Ariel successfully managed the integration, establishing his team as the innovation center for Bio-Rad Life Sciences Group. As a visionary and entrepreneurial leader of Bio-Rad R&D, he created the Protein Technologies R&D group to develop innovative products for life sciences markets. Products developed in Ariel’s group included systems, instrumentation, software, consumables and reagents for imaging, chromatography, gel electrophoresis and blotting, protein interactions and other product lines.

GAYLE KUOKKA   CHIEF FINANCIAL OFFICER

Gayle KuokkaGayle is responsible for finance and general business activities at Biodesy. Her career has been focused in early stage life science companies. Prior to joining Biodesy, she was VP of Finance at Isostent, CFO at Radiant Medical, and sole proprietor of her own consulting practice, working with numerous life science client companies and helping raise more than $100M in venture funding.  Gayle has led the finance, accounting, human resources, facilities, information technology (IT), and manufacturing engineering functions.  She received her Master’s Degree in Industrial Administration (MSIA) from the Tepper School at Carnegie Mellon University in Pittsburgh, Pennsylvania and her BA in Economics, magna cum laude, from the University of Washington in Seattle, Washington.

LOU DIETZ   VICE PRESIDENT OF ENGINEERING

Lou DietzLou leads all engineering activities at Biodesy. He has extensive experience in imaging systems, optical detection, and microfluidics for life science applications, and has developed numerous successful products for the medical diagnostic and bioanalytical research markets. As a consultant, he has designed FDA-cleared products for digital pathology and point-of-care diagnostic testing. He has also held senior engineering management roles in several companies, such as On-Q-ity (formerly CELLective DX), Nanoplex Technologies, and SurroMed, where he has managed teams developing microfluidic devices and instrumentation for analyzing circulating tumor cells in blood samples, automated manufacturing of microparticles and nanoparticles for multiplexed immunoassays, and automated laser-scanning cytometry systems for biomarker discovery and clinical diagnostics. The author or co-author of federal grants totaling $13 million, he holds 15 U.S. patents covering optical instrumentation, nanoparticle manufacturing techniques, and electronic circuitry for communications systems. He received his B.S. and M.S. in Electrical Engineering from Stanford University.

Neil Kennedy   VICE PRESIDENT OF SALES AND MARKETING

Neil KennedyNeil is responsible for worldwide sales, marketing and customer support. He has over 20 years of commercial experience with various life sciences companies including Affymetrix, Millipore and Applied Biosystems. Most recently, Neil was Vice President Commercial Operations at Fluidigm. Prior to joining Fluidigm Neil was Vice President of Sales and Marketing for DVS Sciences, a start-up venture that was acquired by Fluidigm in February of 2014. At DVS, Neil led the commercial strategy and organization that drove significant sales growth and profitability. Before that, Neil held various management and technical roles in the life science market.

SAM KINTZ   VICE PRESIDENT OF BUSINESS DEVELOPMENT AND APPLICATIONS

Sam KintzSam is the head of business development and applications and leads the collaborations team at Biodesy. Previously, Sam was an Analyst at Roche Venture Fund, where he triaged, sourced, and conducted scientific due diligence on investment opportunities in the life sciences industry. While at Roche Venture Fund, Sam worked with Greg and Josh to help shape the strategic vision for Biodesy, Inc. Sam has also worked as a medicinal chemist at Genentech, where he designed and synthesized small-molecule drugs for the treatment of cancer and neurodegenerative diseases. Sam received both his MBA and BS in Chemistry, with Honors, from Stanford University.